Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95
Provided By GlobeNewswire
Last update: Apr 9, 2025
CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody
CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic in 2025
Read more at globenewswire.comNASDAQ:CNTX (6/18/2025, 10:07:38 AM)
0.5946
+0.01 (+2.52%)
Find more stocks in the Stock Screener
